MedComm – Oncology (Mar 2024)

Epigenetic regulation in cancer therapy: From mechanisms to clinical advances

  • Lei Tao,
  • Yue Zhou,
  • Yuan Luo,
  • Jiahao Qiu,
  • Yuzhou Xiao,
  • Jiao Zou,
  • Yu Zhang,
  • Xingchen Liu,
  • Xinyu Yang,
  • Kun Gou,
  • Jing Xu,
  • Xinqi Guan,
  • Xiaobo Cen,
  • Yinglan Zhao

DOI
https://doi.org/10.1002/mog2.59
Journal volume & issue
Vol. 3, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Epigenetic regulation refers to the alteration of gene expression independent of changes in DNA sequence. It involves chemical modifications such as DNA methylation, histone methylation, and histone acetylation, which are regulated by a coordinated interplay of various regulators to ensure precise spatial and temporal regulation of gene expression. Epigenetic aberrations are commonly observed in cancer and are considered as hallmarks of cancer. In recent years, small molecules targeting specific epigenetic regulators have been developed and are demonstrating promising therapeutic potential in preclinical and clinical trials for cancer treatment. In this review, we summarize the essential regulatory mechanisms and dysfunctions of epigenetic regulators involved in DNA methylation, histone methylation, and histone acetylation during tumor development and progression. Moreover, we discuss the current advances and challenges in cancer epigenetic therapy that target these mechanisms in both hematologic malignancies and solid tumors. Finally, we discuss the potential of combining epigenetic drugs with other therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, as a promising approach for cancer treatment. Overall, we aim to enhance the understanding of epigenetic regulation in cancer therapy and explore targeted therapeutic strategies based on these mechanisms, to ultimately advance cancer therapy and improve patient prognosis.

Keywords